|
Exhibit 10.1 UCSD Case Nos. SD2003-049 and SD2004-134
AMENDMENT NO. 2 TO THE LICENSE AGREEMENT EFFECTIVE JUNE 6,
2004 BETWEEN URIGEN PHARMACEUTICALS, INC. AND THE REGENTS OF THE
UNIVERSITY OF CALIFORNIA FOR INVENTION DOCKET NOs. SD2003-049 AND
SD2004-134 "NOVEL INTRAVESICAL THERAPY FOR IMMEDIATE SYMPTOM RELIEF
AND CHRONIC THERAPY IN INTERSTITIAL CYSTITIS PATIENTS" This
amendment to the agreement (this "Amendment 2") is made by and
between Urigen Pharmaceuticals, Inc. located at 27 Maiden Lane,
Suite 595, San Francisco, California 94108 ("LICENSEE") and The
Regents Of The University Of California, a California corporation
having its statewide administrative offices at 1111 Franklin
Street, Oakland, California 946075200 ("UNIVERSITY"), as
represented by its San Diego campus having an address at University
of California, San Diego, Technology Transfer Office, Mail-code
0910, 9500 Gilman Drive, La Jolla, California 92093-0910 ("UCSD").
When signed by both parties, this Amendment 2 is effective
as of the date of the last signature below ("Amendment 2 Effective
Date"). Whereas, LICENSEE and UNIVERSITY entered into a
license agreement for the UCSD Cases cited above, UC Control No.
2004-03-0625, effective June 6, 2004 and reissued effective January
18, 2006 ("Agreement"); Whereas, LICENSEE was previously
known to UNIVERSITY as EGB Advisors LLC, Urigen Holdings Inc. and
Urigen N.A.; Whereas, LICENSEE and UNIVERSITY wish to amend
the Ag
|
